Skip to main content

LEQVIO is for LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1


of cardiovascular events in patients who failed to reach LDL-C goal6†

The effect of LEQVIO® on cardiovascular morbidity and mortality has not been determined.

*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI).7
Based on study (n= 38,110,734) data that evaluated the annual cardiovascular event rates in a subset of guideline-defined high-risk patients of the Family Heart Database which comprises diagnostic, procedure, lab, and prescription data from claims in the US from 2012 to 2021.6

Many patients struggle to adhere to self-administered treatments


of patients discontinue statins within 1 year2-5


of patients discontinue PCSK9 mAbs within 6 months8,9‡§

From an analysis of a large IQVIA open claims dataset of patients (N=72,001) between January 2021 and December 2021.9
§In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAbs (N=13,151) between January 1, 2016, and June 30, 2016, who were followed for a minimum of 6 months after their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.8

For LDL-C reduction when diet and statin are not enough.1


Michael | Patient with Coronary Artery Disease (CAD)
Recent Event: NSTEMI <12 months ago
Recent Procedure: PCI
LDL-C Level: 105 mg/dL
Additional CV Risk Factors: Hyperlipidemia, type 2 diabetes, hypertension 
Current LDL-C Treatment: High-intensity statin

When statins aren’t enough, Look to LEQVIO


*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI).6


See what LEQVIO can do for patients like yours

CAD, coronary artery disease; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; NSTEMI, non–ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; STEMI, ST-elevation myocardial infarction.


Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.


LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 3. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 4. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143-3421. 5. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 6. Myers KD, MacDougall DE, Wilemon KA, et al. Higher cardiovascular event rates for high-risk Americans who do not meet 2018 multidisciplinary guideline on the management of blood cholesterol thresholds. J Clin Lipidol. 2023; 17(suppl 4):e5. doi:10.1016/j.jacl.2023.05.008 7. Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; July 10, 2023. 8. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 9. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2022. 10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625